ADP plays a key role in hemostasis and thrombosis. Despite its early identification in 1961 as the first known aggregating agent, the molecular basis of ADP-induced platelet activation is only beginning to be understood. The present review proposes a model of 3 purinergic receptors contributing separately to the complex process of ADP-induced platelet aggregation: the P2X1 ionotropic receptor, responsible for rapid influx of ionized calcium into the cytosol; the P2Y1 metabotropic receptor, responsible for mobilization of ionized calcium from internal stores, which initiates aggregation; and an as-yet-unidentified P2Y receptor coupled to G(αi2), which is essential for the full aggregation response to ADP. It is probable that this as-yet-unidentified receptor is the molecular target of the ADP- selective antiaggregating drugs ticlopidine and clopidogrel. In addition, it is probably defective in patients with a bleeding diathesis that is characterized by selective impairment of platelet responses to ADP.
ADP receptors and clinical bleeding disorders / M. Cattaneo, C. Gachet. - In: ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. - ISSN 1079-5642. - 19:10(1999), pp. 2281-2285.
|Titolo:||ADP receptors and clinical bleeding disorders|
CATTANEO, MARCO NATALE (Primo)
|Parole Chiave:||Adenosine diphosphate; Bleeding disorders; Platelets; Purino receptors; Thrombosis|
|Settore Scientifico Disciplinare:||Settore MED/09 - Medicina Interna|
|Data di pubblicazione:||1999|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1161/01.ATV.19.10.2281|
|Appare nelle tipologie:||01 - Articolo su periodico|